Please login to the form below

Amarin

This page shows the latest Amarin news and features for those working in and with pharma, biotech and healthcare.

Amarin shares tumble following Vascepa patent loss

is approved by FDA, prevent launch of generic versions of Vascepa,” said John Thero, CEO of Amarin. ... The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.

Latest news

Northsea Therapeutics raises $40m to develop fish oil NASH drug

The outlook for Northsea looks positive given Amarin’s success with its own fish oil-derived drug Vascepa (icosapent ethyl). ... This blockbuster indication has Amarin “aggressively launching” Vascepa in the US, after the company estimated expected
FDA okays Amarin’s Vascepa for cardiovascular risk reduction

Drug is on course for blockbuster sales. Amarin has been given an early Christmas present by the FDA – the approval of its fish oil-derived drug Vascepa to reduce the risk ... The expanded approval for Amarin’s only marketed product was odds on after
Amarin files fish oil-based heart drug Vascepa in Europe

The European Medicines Agency (EMA) has started a review of Irish drugmaker Amarin’s fish oil-derived drug – sold as Vascepa in the US – setting up an approval next year. ... as Amarin starts to expand its salesforce for the drug from 400 to 800
Amarin wins FDA advisory nod for Vascepa cardiovascular expansion

We appreciate both the opportunity to present these results and the committee’s strong vote of confidence,” said John Thero, president and chief executive officer of Amarin. ... These gains also lend more credit to the ongoing speculation that
Amarin up as FDA speeds Vascepa’s cardiovascular claim review

The news has also reignited speculation of a possible buyout of Amarin, with Pfizer rumoured to be among the companies interested in snapping it up. ... That speculation has helped Amarin’s stock rise more than 50% since the outcomes data was first

More from news
Approximately 10 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Medius Deal Watch table for February 2015

aureus and Shigellosis. Corporate acquisition. 190. Amarin/ Eddingpharm. VASCEPA (icosapent ethyl) - triglyceride level reduction.
Pharma deals during November 2012

All may not be plain sailing with this BASF strategy however given the promise of a crowded market place with the anticipated introduction of Amarin's Vascepa next year, to be

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Teva's Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role. Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer. ... Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months: ...
July 2020: diversity and inclusion in clinical trials round-up: COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020: In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...